Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Endocrinology

Blockade of the Stimulatory Effect of Estrogens, OH-Tamoxifen, OH-Toremifene, Droloxifene, and Raloxifene on Alkaline Phosphatase Activity by the Antiestrogen EM-800 in Human Endometrial Adenocarcinoma Ishikawa Cells

Jacques Simard, Rocio Sanchez, Donald Poirier, Sylvain Gauthier, Shankar M. Singh, Yves Merand, Alain Belanger, Claude Labrie and Fernand Labrie
Jacques Simard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rocio Sanchez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald Poirier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvain Gauthier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shankar M. Singh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yves Merand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alain Belanger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claude Labrie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernand Labrie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published August 1997
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Although temporary benefits of tamoxifen therapy are observed in up to 40% of women with breast cancer, this compound, which is known to possess mixed estrogenic and antiestrogenic activities, has been associated with increased risk of endometrial carcinoma. This study compares the effects of the novel nonsteroidal pure antiestrogen EM-800 and related compounds with those of a series of antiestrogens on the estrogen-sensitive alkaline phosphatase (AP) activity in human endometrial adenocarcinoma Ishikawa cells. Exposure to increasing concentrations of up to 1000 nm EM-800 or its active metabolite EM-652 alone failed to affect basal AP activity. In contrast, incubation with 10 nm (Z)-4-OH-tamoxifen, (Z)-4-OH-toremifene, droloxifene, or raloxifene increased the value of this estrogen-sensitive parameter by 3.3-, 3.5-, 2.2-, and 1.6-fold, respectively, a stimulatory effect that was completely reversed by simultaneous exposure to 30 nm EM-800. Moreover, the stimulation of AP activity induced by 1 nm 17β-estradiol was completely reversed by EM-800, EM-652, or ICI-182780, at the IC50 value of 1.98 ± 0.23, 1.01 ± 0.16, and 5.64 ± 0.59 nm, respectively, whereas the partial blockade exerted by (Z)-4-OH-tamoxifen, (Z)-4-OH-toremifene, or raloxifene was observed at IC50 values of 13.5 ± 3.80, 41.0 ± 7.2, and 3.74 ± 0.43 nm, respectively. Thus, as assessed by their activity in the human Ishikawa endometrial carcinoma cells, EM-800 and EM-652 are the most potent known antiestrogens in Ishikawa cells, and, most importantly, they are devoid of the estrogenic activity observed in these human endometrial cancer cells with (Z)-4-OH-tamoxifen, (Z)-4-OH-toremifene, droloxifene, and raloxifene.

Footnotes

  • ↵1 Supported by Endorecherche Inc.

  • ↵2 To whom requests for reprints should be addressed, at MRC Group in Molecular Endocrinology, CHUL Research Center, 2705 Laurier Boulevard, Quebec, Quebec, G1V 4G2 Canada. Phone: (418) 654-2296; Fax: (418) 654-2278.

  • Received April 18, 1997.
  • Accepted June 16, 1997.
  • ©1997 American Association for Cancer Research.
PreviousNext
Back to top
August 1997
Volume 57, Issue 16
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Blockade of the Stimulatory Effect of Estrogens, OH-Tamoxifen, OH-Toremifene, Droloxifene, and Raloxifene on Alkaline Phosphatase Activity by the Antiestrogen EM-800 in Human Endometrial Adenocarcinoma Ishikawa Cells
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Blockade of the Stimulatory Effect of Estrogens, OH-Tamoxifen, OH-Toremifene, Droloxifene, and Raloxifene on Alkaline Phosphatase Activity by the Antiestrogen EM-800 in Human Endometrial Adenocarcinoma Ishikawa Cells
Jacques Simard, Rocio Sanchez, Donald Poirier, Sylvain Gauthier, Shankar M. Singh, Yves Merand, Alain Belanger, Claude Labrie and Fernand Labrie
Cancer Res August 15 1997 (57) (16) 3494-3497;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Blockade of the Stimulatory Effect of Estrogens, OH-Tamoxifen, OH-Toremifene, Droloxifene, and Raloxifene on Alkaline Phosphatase Activity by the Antiestrogen EM-800 in Human Endometrial Adenocarcinoma Ishikawa Cells
Jacques Simard, Rocio Sanchez, Donald Poirier, Sylvain Gauthier, Shankar M. Singh, Yves Merand, Alain Belanger, Claude Labrie and Fernand Labrie
Cancer Res August 15 1997 (57) (16) 3494-3497;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Endocrinology

  • Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment
  • Abstract LB-331: Bidirectional crosstalk between leptin and IGF-1 signaling transactivates epidermal growth factor receptor and promotes invasion and migration of triple-negative breast cancer cells
  • Abstract 1808: The anti-estrogen endoxifen altered bone morphology and reduced muscle function in mice
Show more Endocrinology

Articles

  • Genetic Control of Programmed Cell Death in the Nematode Caenorhabditis elegans
  • Membership of Advisory Council
  • The Prizes
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement